PT - JOURNAL ARTICLE AU - Jian Carrot-Zhang AU - Giovanny Soca-Chafre AU - Nick Patterson AU - Aaron R. Thorner AU - Anwesha Nag AU - Jacqueline Watson AU - Giulio Genovese AU - July Rodriguez AU - Maya K. Gelbard AU - Luis Corrales-Rodriguez AU - Yoichiro Mitsuishi AU - Gavin Ha AU - Joshua D. Campbell AU - Geoffrey R. Oxnard AU - Oscar Arrieta AU - Andres F. Cardona AU - Alexander Gusev AU - Matthew Meyerson TI - Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations AID - 10.1101/2020.09.01.20183913 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.01.20183913 4099 - http://medrxiv.org/content/early/2020/09/02/2020.09.01.20183913.short 4100 - http://medrxiv.org/content/early/2020/09/02/2020.09.01.20183913.full AB - Inherited lung cancer risk, particularly in non-smokers, is poorly understood. Genomic and ancestry analysis of 1,153 lung cancers from Latin America revealed striking associations between Native American ancestry and their somatic landscape, including tumor mutational burden (TMB), and specific driver mutations in EGFR, KRAS, and STK11. A local Native American ancestry risk score predicted EGFR and KRAS mutation frequency more strongly than global ancestry, suggesting that germline genetics (rather than environmental exposure) underlie these disparities.Significance The frequency of somatic EGFR and KRAS mutations in lung cancer varies by ethnicity but we do not understand why. Our study suggests that the variation in EGFR and KRAS is directly associated with genetic ancestry and suggests further studies to identify germline alleles that underpin this association.Competing Interest StatementM.M. is the scientific advisory board chair of OrigiMed; an inventor of patents licensed to LabCorp for EGFR mutation diagnosis and patent applications on EGFR inhibitors; and receives research funding from Bayer, Janssen, Novo Ventures, and Ono Pharmaceuticals.Funding StatementThis study is supported by the V Foundation Translational Research Award and by National Cancer Institute grants R35 CA197568 and R01 CA116020. M.M. is an American Cancer Society Research Professor. J.C.-Z. holds the Banting fellowship. J.D.C. is funded by the LUNGevity Career Development award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol of this work was approved by the ethical and scientific committee in the Instituto Nacional de Cancerologia in Mexico City, the Foundation for Clinical and Applied Cancer Research in Bogota, and Dana-Farber Cancer Institute in Boston for detecting EGFR mutations and further genomic analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSource data is provided as Supplementary Tables. Raw sequencing data is available for research purpose upon request.